What NextGen Jane does

NextGen Jane is a clinical-stage women's health company developing non-invasive molecular diagnostics from menstrual blood collected via a patented at-home tampon kit. The company operates a multiomic analysis platform combining RNA-seq, proteomics, and microbial biomarker profiling from menstrual effluent to associate molecular signatures with gynecological and reproductive health outcomes, including endometriosis, adenomyosis, fibroids, fertility, pregnancy complications, and exploratory neurological biomarker detection (neurofilament light chain on the Siemens Healthineers Atellica platform). The core product, the 'Jane' menstrualome platform, is positioned as the only longitudinal molecular study of women's menstruation, supported by a community-recruitment model in which participants complete an online survey and mail tampon samples to the company's Oakland laboratory for analysis.

The company has no commercial product or pricing today and is funded primarily through non-dilutive U.S. federal grants — three NICHD SBIR awards totaling $5.5 million in 2020, 2022, and 2025 — alongside an approximately $7 million ongoing securities offering disclosed via a 2023 Form D filing and an earlier $9 million Series A in 2019 led by Material Impact. Customer segments consist of clinical study participants across five cohorts: women with suspected or confirmed endometriosis (primary), women with adenomyosis or fibroids (primary), infertility patients (primary), pregnant individuals at risk for pre-eclampsia and preterm labor, and healthy volunteers contributing to a menstrual baseline study. NextGen Jane's go-to-market is community-led participant recruitment through its website and survey portal, supplemented by scientific conference presentations (e.g., 2026 American Academy of Neurology Annual Meeting) and earned media coverage to build evidence credibility. Operating status is active with a small Oakland-based team and three open scientific and quality roles.

Name

NextGen Jane

Legal name

NextGen Jane, Inc.

Website

https://nextgenjane.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

NextGen Jane is a pre-revenue women's health company developing non-invasive molecular diagnostics using patented tampon-based menstrual blood collection and multiomic analysis, targeting endometriosis, adenomyosis, fibroids, fertility, and pregnancy complications.

Ownership category

akta.pro rank

Product category

Women's Health Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

Keywords

• Women's health diagnostics
• Menstrual blood analysis
• Endometriosis diagnostics
• Molecular diagnostics
• Gynecological research

Headquarters

HQ city

Oakland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. NIH Research Grants: SBIR (Small Business Innovation Research) grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of NIH. These non-dilutive funds support clinical validation of the non-invasive endometriosis diagnostic test.
2. Future Diagnostic Services: Planned commercial molecular diagnostic tests for endometriosis, adenomyosis, fibroids, fertility assessment, and gynecologic cancer detection using menstrual blood samples. No commercial product yet available.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

NextGen Jane is building a menstrual blood-based molecular diagnostics platform that uses a patented tampon collection kit to enable non-invasive, at-home sample collection for multiomic analysis. The company is developing diagnostic tests for endometriosis, adenomyosis, fibroids, pregnancy complications, and gynecologic cancers by associating molecular signatures in menstrual blood with discrete health outcomes. The company is currently in clinical validation, with community members contributing samples to build a longitudinal 'menstrualome' database.

Product overview

NextGen Jane operates as a women's health company building a comprehensive menstrualome platform consisting of multiple integrated offerings. The core product is the 'Jane' longitudinal molecular study platform, which uses a patented tampon collection kit to collect menstrual samples from community members for genomic analysis. The platform offers a non-invasive endometriosis diagnostic test that analyzes molecular signals in tampon-collected samples to identify biomarkers associated with gynecological conditions. Additional offerings include a Menstrual Health Assessment providing molecular baselines for understanding menstrual health, and molecular diagnostics for adenomyosis, fibroids, fertility issues, infections, and gynecologic cancers. The company is developing these tests to replace invasive surgical procedures (like laparoscopy for endometriosis) with accessible, at-home molecular testing solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Tampon Collection Kit A patented, specially-designed at-home collection kit containing organic cotton tampons that allows members to collect and mail menstrual samples for genomic analysis. The kit enables non-invasive, routine, longitudinal data collection of uterine tissue-enriched samples for community members participating in NextGen Jane's clinical studies.
• Jane (Menstrualome Platform) A longitudinal molecular study platform of women's menstruation that collects tampon samples to generate genomic information and associate molecular signatures from the uterus with discrete health outcomes. Described as the only longitudinal molecular study of women's menstruation on the planet, designed to expand knowledge of gynecological health through data over time.
• Non-Invasive Endometriosis Diagnostic A non-invasive menstrual-based diagnostic test for endometriosis that uses tampon-collected samples to analyze molecular signals including human and microbial biomarkers shed from the uterine lining. Currently undergoing clinical validation for use in infertility patients, with broader potential applications in fertility, infection, and gynecologic cancer detection.
• Clinical Studies Program A community-based research program enrolling US residents with a uterus to participate in studies covering endometriosis, adenomyosis, fibroids, pregnancy health, and baseline menstrual research. Participants complete surveys and mail tampon samples to the company's Oakland laboratory for molecular analysis.

Quantifiable outcome

• NfL detected in 98 of 99 tampon-collected samples (99% detection rate) using automated immunoassay
• +2 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

One partnership is on record.

• Siemens HealthineerscoreTechnology or Integration · 5 May 2026NextGen Jane presented research at the 2026 American Academy of Neurology Annual Meeting using the Siemens Healthineers Atellica platform for automated immunoassay detection of neurofilament light chain (NfL) in menstrual fluid samples. The company detected NfL in 98 of 99 samples using this platform, demonstrating the feasibility of neurological biomarker detection in menstrual blood.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Teal Health: Teal Health is a women's health startup developing at-home, non-invasive screening for cervical cancer. It is comparable to NextGen Jane as a women's health company replacing invasive in-clinic procedures with at-home sample collection and molecular analysis, addressing underserved gynecological indications.
• Xella Health: Xella Health is identified alongside NextGen Jane as part of the cohort of companies racing toward non-invasive endometriosis diagnostics using menstrual blood. It is an emerging competitor with overlapping sample-type and indication focus.
• Diamens: Diamens is named as a competitor in the menstrual-blood-based endometriosis diagnostics space alongside NextGen Jane. It represents an emerging peer with similar product thesis and target use case.
• Cyclana Bio: Cyclana Bio is cited as one of the firms pursuing non-invasive endometriosis diagnostics via menstrual blood, making it an emerging peer with overlapping technology and indication overlap to NextGen Jane.
• Evvy: Evvy is a vaginal microbiome testing company that uses at-home sample collection and molecular analysis to deliver women's health insights. It shares NextGen Jane's direct-to-consumer, sample-collects-at-home, molecular diagnostics model, though in the microbiome rather than gynecological-disease indication space.

Broad incumbents

• Labcorp Diagnostics: Labcorp is a major clinical laboratory services provider offering molecular and genomic diagnostic testing at scale. It is a broad incumbent that could either compete with or serve as a commercial distribution partner for NextGen Jane's menstrual-based diagnostic tests.
• Myriad Genetics: Myriad Genetics is a large, established molecular diagnostics company with a portfolio of germline and somatic genetic tests, including women's health products. It is comparable as a broad incumbent operating in the same molecular diagnostics space that NextGen Jane is entering, with overlapping technology platforms and reimbursement infrastructure.

Direct peers

• DotLab: DotLab is a women's health diagnostics company developing a non-invasive blood-based test for endometriosis. It is the most directly comparable peer to NextGen Jane, competing for the same clinical use case (non-invasive endometriosis diagnosis) using a different sample type (blood vs. menstrual effluent).
• Celmatix: Celmatix is a women's health biotech focused on fertility and reproductive health through genomics and multiomic analytics. It is comparable to NextGen Jane as a molecular diagnostics platform addressing reproductive health indications, with overlap in target patient populations and underlying technology.
• Endometrics: Endometrics is named in NextGen Jane's competitive landscape as another firm developing non-invasive endometriosis diagnostics using menstrual blood. It is a direct competitor pursuing the same indication and sample type as NextGen Jane.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nextgenjane
• Facebookfacebook.com/nextgenjane
• LinkedInlinkedin.com/company/nextgen-jane-inc.

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NextGen Jane